| Pharmaceutical Information |
| Drug Name |
Cevimeline |
| Drug ID |
BADD_D00424 |
| Description |
Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome. |
| Indications and Usage |
For the treatment of symptoms of dry mouth in patients with Sjögren's Syndrome. |
| Marketing Status |
approved |
| ATC Code |
N07AX03 |
| DrugBank ID |
DB00185
|
| KEGG ID |
D07667
|
| MeSH ID |
C059240
|
| PubChem ID |
2684
|
| TTD Drug ID |
D0Q4CS
|
| NDC Product Code |
64642-011; 63304-479 |
| UNII |
K9V0CDQ56E
|
| Synonyms |
cevimeline | 2-methyspiro(1,3-oxathiolane-5,3)quinuclidine | AF 102B, (trans)-isomer | AF-102B | AF 102B | AF102B | Evoxac | FKS 508 | FKS-508 | SNI 2011 | SNI-2011 | AF 102B, (cis-(+))-isomer | cevimeline hydrochloride |
|
| Chemical Information |
| Molecular Formula |
C10H17NOS |
| CAS Registry Number |
124620-88-8 |
| SMILES |
CC1OC2(CN3CCC2CC3)CS1 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
